Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatment

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 6, 2009, Pages

  Verma, Vivek ^a   Harjai, Kusum ^a   Chhibber, Sanjay ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Biofilm formation; K. pneumoniae; Resistance

Indexed keywords

CIPROFLOXACIN; OUTER MEMBRANE PROTEIN; VIROTHERAPY AGENT; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BACTERIUM ISOLATE; BIOFILM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; VIROTHERAPY; ANIMAL; BACTERIAL COUNT; BAGG ALBINO MOUSE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; PHAGOCYTOSIS; VIROLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; BIOFILMS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; KLEBSIELLA PNEUMONIAE; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PHAGOCYTOSIS;

EID: 76249117473     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp360     Document Type: Article

References (30)

1. Craig BA, Wright MS, Stepanauskas R et al. Co-selection of antibiotic and metal resistance. Trends Microbiol 2006; 14: 176-82.
2. Hoyle BD, Jass J, Costerton JW. The biofilm glycocalyx as a resistance factor. J Antimicrob Chemother 1990; 26: 1-5.
3. Anderl JN, Franklin MJ, Stewart PS. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 2000; 44: 1818-24.
4. Fung-Tomc J, Kolek B, Bonner DP. Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1993; 37: 1289-96.
5. Donlan RM. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol 2009; 17: 66-72.
6. Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci USA 2007; 104: 11197-202.
7. Bedi MS, Verma V, Chhibber S. Amoxicillin and specific bacteriophage can be used together for the eradication of biofilm of Klebsiella pneumoniae B5055. World J Microbiol Biotech 2009; 25: 1145-51.
8. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48: 5-16.
9. Reed RW, Reed GB. "Drop plate" method of counting viable bacteria. Can J Res 1948; 26: 317-26.
10. Verma V, Harjai K, Chhibber S. Characterization of a T7-like lytic bacteriophage of Klebsiella pneumoniae B5055: a potential therapeutic agent. Curr Microbiol 2009; 59: 274-81.
11. Adams MH. Bacteriophages. New York: Interscience, 1959.
12. Nilsson L, Soren L. Selective growth of resistant variants during incubation of Enterobacteriaceae with four aminoglycosides. J Antimicrob Chemother 1986; 18: 317-24.
13. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA, 2000.
14. Drago L, Vecchi ED, Nicola L et al. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with b-lactams and amikacin. J Antimicrob Chemother 2005; 56: 353-9.
15. Hanlon GW, Denyer SP, Olliff CJ. Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 2001; 67: 2746-53.
16. Dubois M, Giles VA, Hamilton JK et al. Colorimetric methods for determination of sugars and related substances. Anal Chem 1956; 28: 350-6.
17. Filip C, Fletcher G, Wulff JL et al. Solubilization of the cytoplasmic membrane of Escherichia coli by the ionic detergent sodiumlauryl sarcosinate. J Bacteriol 1973; 115: 717-22.
18. Clements A, Gaboriaud F, Duval JFL et al. The major surface-associated saccharides of Klebsiella pneumoniae contribute to host cell association. PLoS ONE 2008; 3: e3817.
19. Hampton MB, Winterbourn CC. Methods for quantifying phagocytosis and bacterial killing by human neutrophils. J Immunol Methods 1999; 232: 15-22.
20. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001; 9: 34-9.
21. Stewart PS, Mukherjee PK, Ghannoum MA. Biofilm antimicrobial resistance. In: Ghannoum M, O'Toole GA, eds. Microbial Biofilms. Washington, DC: ASM Press, 2004; 250-68.
22. Schoolnik GK, Summers WC, Watson JD. Phage offer a real alternative. Nat Biotechnol 2004; 22: 505-7.
23. Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci USA 2009; 106: 4629-34.
24. Anderl JN, Zahller J, Roe F et al. Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 2003; 47: 1251-6.
25. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416: 740-3.
26. Balestrino D, Ghigo JM, Charbonnel N et al. The characterization of functions involved in the establishment and maturation of Klebsiella pneumoniae in vitro biofilm reveals dual roles for surface exopolysaccharides. Environ Microbiol 2008; 10: 685-701.
27. Chhibber S, Aggarawal S, Yadav V. Contribution of capsular and lipopolysaccharide antigens to the pathogenesis of Klebsiella pneumoniae respiratory tract infection. Folia Microbiol 2003; 48: 699-702.
28. Kohanski MA, Dwyer DJ, Hayete B et al. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007; 130: 797-810.
29. Inal JM. Phage therapy: a reappraisal of bacteriophages as antibiotics. Arch Immunol Ther Exp (Warsz) 2003; 51: 237-44.
30. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 2005; 49: 2874 8.